The Specific Management of Anemia and Hypertension in Renal Transplant ( SMAhRT ) recipients study was designed to examine the cardiovascular benefits of RAS blockade with telmisartan 80 mg versus placebo , and Hb management with darbepoetin in a randomized , double-blind , single-center controlled trial in 2,000 patients over 3 years .